^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CART-38
i
Other names: CART-38
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University of Pennsylvania
Drug class:
CD38-targeted CAR-T immunotherapy
Related drugs:
over1year
CART-38 in Adult AML and MM Patients (clinicaltrials.gov)
P1, N=36, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
Enrollment open
|
CD38 (CD38 Molecule) • CD34 (CD34 molecule)
|
CD38 expression
|
cyclophosphamide • fludarabine IV • CART-38
over1year
CD38 as a pan-hematologic target for chimeric antigen receptor T cells. (PubMed, Blood Adv)
In a xenograft model of normal human hematopoiesis, CART-38 resulted in the expected reduction of hematopoietic progenitors, which warrants caution and careful monitoring of this potential toxicity when translating this new immunotherapy into the clinic. Deploying CART-38 against multiple CD38-expressing malignancies is significant, as it expands the potential for this novel therapy to impact diverse patient populations.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression
|
CART-38
2years
CART-38 in Adult AML and MM Patients (clinicaltrials.gov)
P1, N=36, Not yet recruiting, University of Pennsylvania | Trial completion date: Sep 2040 --> May 2041 | Initiation date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2040 --> May 2041
Trial completion date • Trial initiation date • Trial primary completion date
|
CD38 (CD38 Molecule) • CD34 (CD34 molecule)
|
CD38 expression
|
cyclophosphamide • fludarabine IV • CART-38
over2years
CART-38 in Adult AML and MM Patients (clinicaltrials.gov)
P1, N=36, Not yet recruiting, University of Pennsylvania
New P1 trial
|
CD38 (CD38 Molecule) • CD34 (CD34 molecule)
|
CD38 expression
|
cyclophosphamide • fludarabine IV • CART-38
Share via
